Clinical Trials
42
Trial Phases
4 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (42 trials with phase data)• Click on a phase to view related trials
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
- Conditions
- LymphomaHodgkin LymphomaNon-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 49
- Registration Number
- NCT06915246
- Locations
- 🇺🇸
City of Hope Phoenix, Goodyear, Arizona, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸City of Hope Atlanta, Newnan, Georgia, United States
A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 565
- Registration Number
- NCT05215418
- Locations
- 🇺🇸
Clinical Site, Norfolk, Virginia, United States
🇺🇸Clinical site, Salt Lake City, Utah, United States
A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity
- Conditions
- Adolescent ObesityObesity in AdolescenceAdolescent Overweight
- Interventions
- Drug: VI-0521 oral capsuleDrug: Placebo oral capsuleBehavioral: Lifestyle Modification
- First Posted Date
- 2019-04-22
- Last Posted Date
- 2022-09-10
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 223
- Registration Number
- NCT03922945
- Locations
- 🇺🇸
Intend Research, LLC, Norman, Oklahoma, United States
A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents
- Conditions
- Pediatric ObesityChildhood Obesity
- Interventions
- Drug: VI-0521 Mid DoseDrug: PlaceboDrug: VI-0521 Top Dose
- First Posted Date
- 2016-03-21
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 42
- Registration Number
- NCT02714062
- Locations
- 🇺🇸
Research Facility, Charleston, South Carolina, United States
Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects
- First Posted Date
- 2014-09-01
- Last Posted Date
- 2017-11-07
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 51
- Registration Number
- NCT02229214
- Locations
- 🇺🇸
Research Center, Lakewood, Colorado, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 9
- Next
News
Adolescent Obesity Medication Prescriptions Surge 301% Despite Persistent Access Barriers
Obesity medication prescriptions among US adolescents aged 12-17 years increased by 301.7% between 2020 and 2023, driven primarily by FDA approvals of semaglutide and phentermine-topiramate for pediatric use.
VIVUS Launches QSYMIA in UAE, Marking First Middle East Market for Obesity Treatment
VIVUS LLC has launched QSYMIA (phentermine and topiramate extended-release) in the United Arab Emirates for treating obesity in adults and children aged 12 and older, marking the first Middle Eastern country to approve the medication.